Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

XIth Eurasian Hematology-Oncology Congress - EHOC 2020
M

Novel Approaches for PV: Can We Achieve CHR and Improve Disease Burden With Ropeginterferon Alfa-2b vs. SoC? Is 2L Ruxolitinib the Best Choice for HU-Resistant Patients?

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Martin Ellis
By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Martin Ellis
12 views
January 18, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
MDS and MPN
21:56

Leukemic Transformations of MPNs: What Mutations Are Associated With…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

T. Mughal

252 views
25:23

MDS Essentials: How Common Are Comorbidities? Should Risk Score Dete…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Çetiner

78 views
09:57

LR-MDS: Are ESAs Effective in the Treatment of Anemia? Is PLT Transf…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Mittelman

24 views
10:25

HR-MDS: Are HMAs the Best Option? Should We Consider Changing the Pa…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Mittelman

117 views
22:45

Novel Approaches for PV: Can We Achieve CHR and Improve Disease Burd…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Ellis

12 views
12:47

MDS Updates: Can We Achieve Long-Term Transfusion Independence With …

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

G. Garcia-Manero

310 views